BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 38339274)

  • 21. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
    Liu L; Dong X
    PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen receptor mutations for precision medicine in prostate cancer.
    Shiota M; Akamatsu S; Tsukahara S; Nagakawa S; Matsumoto T; Eto M
    Endocr Relat Cancer; 2022 Oct; 29(10):R143-R155. PubMed ID: 35900853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Origin, Expression Regulation, and Biological Function of Androgen Receptor Splicing Variant 7 in Prostate Cancer.
    Chen Y; Lan T
    Urol Int; 2021; 105(5-6):337-353. PubMed ID: 32957106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
    Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
    Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer.
    Agarwal N; Zhang T; Efstathiou E; Sayegh N; Engelsberg A; Saad F; Fizazi K
    Eur J Cancer; 2023 Oct; 192():113249. PubMed ID: 37672815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
    Cai Z; Chen W; Zhang J; Li H
    Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer.
    Mohler ML; Sikdar A; Ponnusamy S; Hwang DJ; He Y; Miller DD; Narayanan R
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic Approaches to Targeting Androgen Receptor Splice Variants.
    Daniels VA; Luo J; Paller CJ; Kanayama M
    Cells; 2024 Jan; 13(1):. PubMed ID: 38201308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
    Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
    Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The molecular underpinnings of prostate cancer: impacts on management and pathology practice.
    Rodrigues DN; Boysen G; Sumanasuriya S; Seed G; Marzo AM; de Bono J
    J Pathol; 2017 Jan; 241(2):173-182. PubMed ID: 27753448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ncRNA-mediated overexpression of ubiquitin-specific proteinase 13 contributes to the progression of prostate cancer via modulating AR signaling, DNA damage repair and immune infiltration.
    Cui X; Yu H; Yao J; Li J; Li Z; Jiang Z
    BMC Cancer; 2022 Dec; 22(1):1350. PubMed ID: 36564767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
    Pilling A; Kim SH; Hwang C
    Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling.
    Köhler A; Demir U; Kickstein E; Krauss S; Aigner J; Aranda-Orgillés B; Karagiannidis AI; Achmüller C; Bu H; Wunderlich A; Schweiger MR; Schaefer G; Schweiger S; Klocker H; Schneider R
    Mol Cancer; 2014 Jun; 13():146. PubMed ID: 24913494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.
    Labriola MK; Atiq S; Hirshman N; Bitting RL
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):301-309. PubMed ID: 33168966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities.
    Yu EM; Hwang MW; Aragon-Ching JB
    Res Rep Urol; 2023; 15():519-529. PubMed ID: 38050587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficient Everolimus Treatment for Metastatic Castration Resistant Prostate Cancer with
    Yu Z; Wei W; Liu H; Pan E; Yang P; Jiang K
    Onco Targets Ther; 2021; 14():5423-5428. PubMed ID: 34916807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications.
    Aurilio G; Cimadamore A; Mazzucchelli R; Lopez-Beltran A; Verri E; Scarpelli M; Massari F; Cheng L; Santoni M; Montironi R
    Cells; 2020 Dec; 9(12):. PubMed ID: 33321757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.
    Huang KC; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
    Cancer Biol Ther; 2014 Sep; 15(9):1120-8. PubMed ID: 24972028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.